As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

A team of researchers led by Dr. KIM V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of ...

To find the best formulation of LNP to bring mRNA into cells, the company teamed up with Dr. Bruno De Geest (Ghent University) because of his expertise in developing LNPs. The eTheRNA research ...

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a ...

Sunshine Biopharma's K1.1 mRNA-LNP reduced human HCC tumor growth in mice with good tolerability under repeated dosing. The company's 2024 revenue rose 45% year over year to $34.9 million.

Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...